These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 7912363)

  • 1. Ciprofibrate and lipid profile.
    Chandler HA; Batchelor AJ
    Lancet; 1994 Jul; 344(8915):128-9. PubMed ID: 7912363
    [No Abstract]   [Full Text] [Related]  

  • 2. Impressive lipid changes following hypolipidaemic drug administration can unveil subclinical hyperthyroidism.
    Liberopoulos E; Miltiadous G; Elisaf M
    Diabetes Obes Metab; 2001 Apr; 3(2):97-8. PubMed ID: 11298731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Aguilar-Salinas CA; Fanghänel-Salmón G; Meza E; Montes J; Gulías-Herrero A; Sánchez L; Monterrubio-Flores EA; González-Valdez H; Gómez Pérez FJ
    Metabolism; 2001 Jun; 50(6):729-33. PubMed ID: 11398153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal lipid profiles on fibrate derivatives.
    McLeod AJ; Warren RJ; Armitage M
    Lancet; 1996 Jan; 347(8996):261. PubMed ID: 8551900
    [No Abstract]   [Full Text] [Related]  

  • 5. Lipid profiles on fibric-acid derivatives.
    Capps NE
    Lancet; 1994 Sep; 344(8923):684-5. PubMed ID: 7915370
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia.
    Betteridge DJ; O'Bryan-Tear CG
    Postgrad Med J; 1996 Dec; 72(854):739-43. PubMed ID: 9015467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of 4S evidence on baseline lipid levels.
    Durrington PN
    Lancet; 1995 Jul; 346(8968):181. PubMed ID: 7661979
    [No Abstract]   [Full Text] [Related]  

  • 8. The atherogenic role of triglycerides and small, dense low density lipoproteins: impact of ciprofibrate therapy.
    Chapman MJ; Bruckert E
    Atherosclerosis; 1996 Jul; 124 Suppl():S21-8. PubMed ID: 8831912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects.
    Hernández-Mijares A; Lluch I; Vizcarra E; Martínez-Triguero ML; Ascaso JF; Carmena R
    Nutr Metab Cardiovasc Dis; 2000 Feb; 10(1):1-6. PubMed ID: 10812581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects.
    Gajdos M; Mongiellová V; Huttová D; Cibulová L; Krivosíková Z; Spustová V; Dzúrik R
    J Cardiovasc Pharmacol; 2001 Nov; 38(5):651-6. PubMed ID: 11602811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ciprofibrate and lipid profile.
    McLeod AJ; Warren RJ; Armitage M
    Lancet; 1994 Oct; 344(8927):955. PubMed ID: 7934365
    [No Abstract]   [Full Text] [Related]  

  • 12. [The treatment of chronic ischemic heart disease: the potentials for hypolipidemic correction using current drugs].
    Tashchuk VK; Makoviĭchuk IO; Bilets'kyĭ SV; Hrechko SI; Polishchuk OIu; Turubarova NA
    Lik Sprava; 1998; (5):101-3. PubMed ID: 9793321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia.
    Bruckert E; Dejager S; Chapman MJ
    Atherosclerosis; 1993 Apr; 100(1):91-102. PubMed ID: 8318067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects.
    Sposito AC; Mansur AP; Maranhão RC; Rodrigues-Sobrinho CR; Coelho OR; Ramires JA
    Braz J Med Biol Res; 2001 Feb; 34(2):177-82. PubMed ID: 11175492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus.
    Evans M; Anderson RA; Graham J; Ellis GR; Morris K; Davies S; Jackson SK; Lewis MJ; Frenneaux MP; Rees A
    Circulation; 2000 Apr; 101(15):1773-9. PubMed ID: 10769276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio, the lipoprotein particle size and the cholesterol esterification rate: changes during lipanor therapy].
    Dobiásová M; Frohlich J
    Vnitr Lek; 2000 Mar; 46(3):152-6. PubMed ID: 11048517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease.
    Papadakis JA; Ganotakis ES; Jagroop IA; Winder AF; Mikhailidis DP
    Int J Cardiol; 1999 Jun; 69(3):237-44. PubMed ID: 10402106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of ciprofibrate on the endothelial dysfunction of patients with combined dyslipidemia].
    Kovács I; Tarján J; Császár A
    Orv Hetil; 2001 Apr; 142(15):775-9. PubMed ID: 11367862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of etofibrate on LDL-subtype distribution in patients with diabetic dyslipoproteinemia.
    Geiss HC; Dietlein M; Parhofer KG
    Exp Clin Endocrinol Diabetes; 2003 Sep; 111(6):322-4. PubMed ID: 14520596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The action of a fibric acid derivative on lipid metabolism].
    Filip M; Păduraru I; Nechifor M; Dănilă GH; Popovici I; Filip FM; Poşircă F
    Rev Med Chir Soc Med Nat Iasi; 1989; 93(3):573-6. PubMed ID: 2636755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.